Panayiotis P. Panayiotidis

Athens, ESYE31, Greece

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 113 publications

Deciphering the role of HMGA2 and let-7 microRNAs in myelodysplastic neoplasms with bone marrow fibrosis.

Deciphering the role of HMGA2 and let-7 microRNAs in myelodysplastic neoplasms with bone marrow fibrosis.

Journal: Leukemia & lymphoma
Published: February 24, 2026

First-line ibrutinib plus venetoclax for non-blastoid mantle cell lymphoma in patients ≥65 years or with TP53 mutations.

First-line ibrutinib plus venetoclax for non-blastoid mantle cell lymphoma in patients ≥65 years or with TP53 mutations.

Journal: Blood
Published: December 19, 2025

Comprehensive molecular characterization of treatment-free remission and molecular relapse in chronic myeloid leukemia patients: the EURO-SKI Biomarker Study.

Comprehensive molecular characterization of treatment-free remission and molecular relapse in chronic myeloid leukemia patients: the EURO-SKI Biomarker Study.

Journal: Leukemia
Published: November 28, 2025

Venetoclax-Rituximab and Emerging Treatment Strategies After c-BTKi Exposure in Relapsed/Refractory CLL: A Real-World Cohort and Literature Overview.

Venetoclax-Rituximab and Emerging Treatment Strategies After c-BTKi Exposure in Relapsed/Refractory CLL: A Real-World Cohort and Literature Overview.

Journal: Cancers
Published: September 04, 2025

Acalabrutinib resistance in a CLL patient harboring a C515 mutation in the BTK-C isoform.

Acalabrutinib resistance in a CLL patient harboring a C515 mutation in the BTK-C isoform.

Journal: Leukemia & lymphoma
Published: June 16, 2025

Novel isolated mutations at the C515 residue of BTK in a CLL patient associated with acalabrutinib resistance.

Novel isolated mutations at the C515 residue of BTK in a CLL patient associated with acalabrutinib resistance.

Journal: Leukemia & lymphoma
Published: May 16, 2025

Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy.

Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy.

Journal: Blood advances
Published: May 06, 2025

Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy.

Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy.

Journal: Blood advances
Published: May 06, 2025

Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy.

Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy.

Journal: Blood advances
Published: May 06, 2025

Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial.

Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial.

Journal: Lancet (London, England)
Published: March 26, 2025

Lenalidomide Efficacy in Patients with MDS and Del-5q: Real-World Data from the Hellenic (Greek) National Myelodysplastic & Hypoplastic Syndromes Registry (EAKMYS).

Lenalidomide Efficacy in Patients with MDS and Del-5q: Real-World Data from the Hellenic (Greek) National Myelodysplastic & Hypoplastic Syndromes Registry (EAKMYS).

Journal: Cancers
Published: February 28, 2025

Validation of the simplified geriatric prognostic index in a Hellenic database of older patients (≥ 70 years old) with diffuse large B-cell lymphoma and similar disorders.

Validation of the simplified geriatric prognostic index in a Hellenic database of older patients (≥ 70 years old) with diffuse large B-cell lymphoma and similar disorders.

Journal: Annals of hematology
Published: January 08, 2025
Showing 1-12 of 113

Last Updated: 09/26/2026